NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. The company has a strategic alliance with Pharmaceutical Product Development Inc. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Testing laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NEO
CUSIPN/A
Phone239-768-0600
Debt
Debt-to-Equity Ratio0.77
Current Ratio1.74
Quick Ratio1.59
Price-To-Earnings
Trailing P/E Ratio211.17
Forward P/E Ratio140.78
P/E Growth6.94
Sales & Book Value
Annual Sales$258.61 million
Price / Sales4.00
Cash Flow$0.4840 per share
Price / Cash26.18
Book Value$2.15 per share
Price / Book5.89
Profitability
EPS (Most Recent Fiscal Year)$0.06
Net Income$-840,000.00
Net Margins-0.98%
Return on Equity-0.36%
Return on Assets-0.18%
Miscellaneous
Employees1,030
Outstanding Shares81,640,000
Market Cap$1.02 billion
NeoGenomics (NASDAQ:NEO) Frequently Asked Questions
What is NeoGenomics' stock symbol?
NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."
How were NeoGenomics' earnings last quarter?
NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings results on Tuesday, July, 24th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.04 by $0.01. The medical research company earned $67.70 million during the quarter, compared to analyst estimates of $66.40 million. NeoGenomics had a negative return on equity of 0.36% and a negative net margin of 0.98%. NeoGenomics's quarterly revenue was up 8.7% compared to the same quarter last year. During the same period last year, the company earned $0.04 EPS. View NeoGenomics' Earnings History.
When is NeoGenomics' next earnings date?
What guidance has NeoGenomics issued on next quarter's earnings?
NeoGenomics issued an update on its FY18 earnings guidance on Tuesday, July, 24th. The company provided earnings per share guidance of $0.12-0.17 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.18. The company issued revenue guidance of $260-272 million, compared to the consensus revenue estimate of $265.24 million.
What price target have analysts set for NEO?
8 analysts have issued 12-month price objectives for NeoGenomics' shares. Their predictions range from $9.00 to $24.00. On average, they anticipate NeoGenomics' share price to reach $17.50 in the next year. This suggests a possible upside of 38.1% from the stock's current price. View Analyst Price Targets for NeoGenomics.
What is the consensus analysts' recommendation for NeoGenomics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics.
What are Wall Street analysts saying about NeoGenomics stock?
Here are some recent quotes from research analysts about NeoGenomics stock:
- 1. According to Zacks Investment Research, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. " (7/19/2018)
- 2. BTIG Research analysts commented, "Raising Our PT Earlier this week, we hosted investor meetings with Chairman and CEO Bill Bonello. The general tone was upbeat with majority of the discussions focused on the oncology market opportunity, competitive landscape given recent M&A and use of cash. We felt the overarching theme was the breadth of NEO’s testing capabilities being a competitive differentiator particularly on the clinical trial side. The recently announced agreement with PPD (Private) to be the chief oncology provider would be upside to our current estimates. We are increasing our target EV/sales multiple and PT to $15 (from $11) on increased confidence in Pharma Services, and continued market share capture of clinical testing. Additionally, as NEO moves upstream into higher-end testing, we feel its multiple should more closely match those of specialty cancer testing peers." (6/21/2018)
Who are some of NeoGenomics' key competitors?
Some companies that are related to NeoGenomics include ABLYNX NV/ADR (ABLX), DiaSorin (DIA), Cantel Medical (CMD), Immunomedics (IMMU), ABCAM PLC/ADR (ABCZY), Ultragenyx Pharmaceutical (RARE), ConvaTec Group (CTEC), Ablynx (ABLYF), GW Pharmaceuticals PLC- (GWPH), Ansell (ANN), Amedisys (AMED), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP), Horizon Pharma (HZNP) and Enerplus (ERF).
Who are NeoGenomics' key executives?
NeoGenomics' management team includes the folowing people:
- Mr. Douglas M. VanOort, Chairman & CEO (Age 63)
- Mr. Steven C. Jones, Exec. VP & Director (Age 55)
- Dr. Maher Albitar, Chief Medical Officer and Director of R&D (Age 63)
- Mr. George A. Cardoza, Pres of Pharma Services Division (Age 56)
- Mr. Robert J. Shovlin, Pres of Clinical Services Division (Age 47)
Has NeoGenomics been receiving favorable news coverage?
News stories about NEO stock have trended somewhat negative recently, according to Accern Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NeoGenomics earned a news impact score of -0.03 on Accern's scale. They also assigned news stories about the medical research company an impact score of 45.24 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for NeoGenomics.
Who are NeoGenomics' major shareholders?
NeoGenomics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (7.54%), First Light Asset Management LLC (6.32%), BlackRock Inc. (5.08%), Russell Investments Group Ltd. (3.05%), Artisan Partners Limited Partnership (2.66%) and Granite Investment Partners LLC (2.01%). Company insiders that own NeoGenomics stock include Alison L Hannah, Jennifer Balliet, Maher Albitar, Robert J Shovlin, Steven A Ross, Steven C Jones and Steven G Brodie. View Institutional Ownership Trends for NeoGenomics.
Which major investors are selling NeoGenomics stock?
NEO stock was sold by a variety of institutional investors in the last quarter, including Gabelli Funds LLC, Cowen Prime Services LLC, Russell Investments Group Ltd., Bank of America Corp DE, Gamco Investors INC. ET AL, Penn Capital Management Co. Inc., Summit Creek Advisors LLC and Segall Bryant & Hamill LLC. Company insiders that have sold NeoGenomics company stock in the last year include Jennifer Balliet, Robert J Shovlin, Steven A Ross and Steven C Jones. View Insider Buying and Selling for NeoGenomics.
Which major investors are buying NeoGenomics stock?
NEO stock was acquired by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, BlackRock Inc., Dimensional Fund Advisors LP, Emerald Mutual Fund Advisers Trust, Hussman Strategic Advisors Inc., EAM Global Investors LLC, Emerald Advisers Inc. PA and Granahan Investment Management Inc. MA. View Insider Buying and Selling for NeoGenomics.
How do I buy shares of NeoGenomics?
Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NeoGenomics' stock price today?
One share of NEO stock can currently be purchased for approximately $12.67.
How big of a company is NeoGenomics?
NeoGenomics has a market capitalization of $1.02 billion and generates $258.61 million in revenue each year. The medical research company earns $-840,000.00 in net income (profit) each year or $0.06 on an earnings per share basis. NeoGenomics employs 1,030 workers across the globe.
How can I contact NeoGenomics?
NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]
MarketBeat Community Rating for NeoGenomics (NASDAQ NEO)
MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe NEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
